The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles
Abstract
Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs+CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX+CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX+CUR-PBCA-NPs or CUR+DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Especially, anticancer drugs encapsulated in polymeric micelles have shown a better accumulation in the targeted site, thus reducing side effects on noncancerous tissues [46,47,48].”
From Recent Advances in Nanomicelles Delivery Systems. (2020) · cites this paper as [46]
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 2,550
Aggarwal, B. B., & Harikumar, K. B. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.06.010 · Cited by 2,139
Cheng, A., Hsu, C., Lin, J., Hsu, M. M., Ho, Y., Shen, T. S., Ko, J. Y., Lin, J.-T., Lin, B., Ming-Shiang, W., et al. (2001) · PubMed · Cited by 2,071
Kunnumakkara, A. B., Anand, P., & Aggarwal, B. B. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.009 · Cited by 1,083
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications
Vauthier, C., Dubernet, C., Fattal, E., Pinto‐Alphandary, H., & Couvreur, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00041-3 · Cited by 537
Targeted nanoparticles for cancer therapy
Gu, F., Karnik, R., Wang, A. Z., Alexis, F., Levy‐Nissenbaum, E., Hong, S., Langer, R., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 520
Ganta, S., & Amiji, M. M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 489
Targeted Nanoparticles for Cancer Therapy
Reddy, G. S. N. (2021) · Journal of Bioanalysis & Biomedicine · Cited by 401
Notarbartolo, M., Poma, P., Perri, D., Dusonchet, L., Cervello, M., & D’Alessandro, N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.051 · Cited by 317
Cited by
Sorted by citations
Naksuriya, O., Okonogi, S., Schiffelers, R. M., & Hennink, W. E. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.090 · Cited by 856
Biopolymer nano-particles and natural nano-carriers for nano-encapsulation of phenolic compounds
Esfanjani, A. F., & Jafari, S. M. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.06.053 · Cited by 556
Recent progress in nanomedicine for enhanced cancer chemotherapy
Wei, G., Wang, Y., Yang, G. Y., Wang, Y., & Ju, R. (2021) · Theranostics · doi:10.7150/thno.57828 · Cited by 484
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A. K., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 400
Metadata
- Authors
- Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J.
- Affiliations
- Central South University (CN)
- University of Kentucky (US)
- Emory University (US)
- Corresponding author
- Zhao, Jinfeng
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 426
- Issue
- 1-2
- Pages
- 193-201
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W2005475049
- Cited by
- 194
- References
- 38
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 8 · 2021: 9 · 2020: 19 · 2019: 22 · 2018: 18 · 2017: 18 · 2016: 17 · 2015: 19 · 2014: 16 · 2013: 12 · 2012: 5
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lotus Scholars Program (200734)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- multidrug resistance reversal, doxorubicin, curcumin, chitosan, co-encapsulation, MCF-7/ADR cells, breast cancer, anticancer drug delivery, combination chemotherapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Calorimetry, Differential Scanning, Chemistry, Pharmaceutical, Chromatography, Gel, Curcumin, Doxorubicin, Drug Carriers, Drug Combinations, Drug Compounding, Enbucrilate, Female, Humans, Particle Size, Technology, Pharmaceutical, Down-Regulation, Spectroscopy, Fourier Transform Infrared, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Nanotechnology, Cell Line, Tumor, Chitosan, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
